PCA062
Total Payments
$345,777
Transactions
11
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $132,501 | 1 | 0 |
| 2018 | $74,312 | 5 | 0 |
| 2017 | $138,964 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $345,777 | 11 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I MULTICENTER OPEN LABEL DOSE ESCALATION AND EXPANSION STUDY OF PCA062 ADMINISTERED INTRAVENOUSLY IN ADULT PATIENTS WITH PCAD POSITIVE TUMORS | Novartis Pharmaceuticals Corporation | $345,777 | 0 |
Top Doctors Receiving Payments for PCA062
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Antonio, TX | $345,777 | 11 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $345,777
Product Information
- Type Drug
- Total Payments $345,777
- Total Doctors 0
- Transactions 11
About PCA062
PCA062 is a drug associated with $345,777 in payments to 0 healthcare providers, recorded across 11 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2019. In 2019, $132,501 was paid across 1 transactions to 0 doctors.
The most common payment nature for PCA062 is "Unspecified" ($345,777, 100.0% of total).
PCA062 is associated with 1 research study, including "A PHASE I MULTICENTER OPEN LABEL DOSE ESCALATION AND EXPANSION STUDY OF PCA062 ADMINISTERED INTRAVENOUSLY IN ADULT PATIENTS WITH PCAD POSITIVE TUMORS" ($345,777).